Effects of Rosuvastatin on Coronary Flow Reserve and Metabolic Mismatch in Patients With Heart Failure (from the CORONA Study)

American Journal of Cardiology

Volumn 105, Issue 4, 2010, Pages 517-521

  van der Harst, Pim ^a   Slart, Riemer H J A ^a   Tio, Rene A ^a   Dunselman, Peter H J M ^b   Willemsen, Antoon T M ^a   van den Heuvel, Ad F M ^a   Voors, Adriaan A ^a   van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA N 13; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY FLOW RESERVE; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE TEST; FEMALE; FRACTIONAL FLOW RESERVE; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REST; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY CIRCULATION; DIPYRIDAMOLE; EXERCISE TEST; FEMALE; FLUOROBENZENES; FLUORODEOXYGLUCOSE F18; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; MYOCARDIUM; NETHERLANDS; PILOT PROJECTS; PYRIMIDINES; RADIOPHARMACEUTICALS; SULFONAMIDES; TOMOGRAPHY, EMISSION-COMPUTED; VASODILATOR AGENTS;

EID: 75349100259     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.021     Document Type: Article

References (22)

1. van der Harst P., Voors A.A., van Gilst W.H., Bohm M., and van Veldhuisen D.J. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 3 (2006) e333
2. GISSI-HF I. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1231-1239
3. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson A., Hradec J., Janosi A., Kamensky G., Komajda M., Korewicki J., Kuusi T., Mach F., Mareev V., McMurray J.J., Ranjith N., Schaufelberger M., Vanhaecke J., van Veldhuisen D.J., Waagstein F., Wedel H., and Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
4. van der Harst P., Voors A.A., van Gilst W.H., Bohm M., and van Veldhuisen D.J. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 71 (2006) 443-454
5. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Stromberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K., Vahanian A., Camm J., De C.R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Tendera M., Auricchio A., Bax J., Bohm M., Corra U., della B.P., Elliott P.M., Follath F., Gheorghiade M., Hasin Y., Hernborg A., Jaarsma T., Komajda M., Kornowski R., Piepoli M., Prendergast B., Tavazzi L., Vachiery J.L., Verheugt F.W., Zamorano J.L., and Zannad F. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10 (2008) 933-989
6. O'Driscoll G., Green D., and Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997) 1126-1131
7. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
8. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356 (2007) 1140-1151
9. Van den Heuvel A.F., van Veldhuisen D.J., van der Wall E.E., Blanksma P.K., Siebelink H.M., Vaalburg W.M., van Gilst W.H., and Crijns H.J. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 35 (2000) 19-28
10. Choi Y., Hawkins R.A., Huang S.C., Gambhir S.S., Brunken R.C., Phelps M.E., and Schelbert H.R. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18F]fluoro-2-deoxy-d-glucose studies. J Nucl Med 32 (1991) 733-738
11. Marinho N.V., Keogh B.E., Costa D.C., Lammerstma A.A., Ell P.J., and Camici P.G. Pathophysiology of chronic left ventricular dysfunction. New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation 93 (1996) 737-744
12. Blanksma P.K., Willemsen A.T., Meeder J.G., de Jong R.M., Anthonio R.L., Pruim J., Vaalburg W., and Lie K.I. Quantitative myocardial mapping of perfusion and metabolism using parametric polar map displays in cardiac PET. J Nucl Med 36 (1995) 153-158
13. Gambhir S.S., Schwaiger M., Huang S.C., Krivokapich J., Schelbert H.R., Nienaber C.A., and Phelps M.E. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med 30 (1989) 359-366
14. de Boer R.A., Pinto Y.M., and van Veldhuisen D.J. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10 (2003) 113-126
15. de Jong R.M., Blanksma P.K., Cornel J.H., Van den Heuvel A.F., Siebelink H.M., Vaalburg W., and van Veldhuisen D.J. Endothelial dysfunction and reduced myocardial perfusion reserve in heart failure secondary to coronary artery disease. Am J Cardiol 91 (2003) 497-500
16. Tsagalou E.P., Nastasiou-Nana M., Agapitos E., Gika A., Drakos S.G., Terrovitis J.V., Ntalianis A., and Nanas J.N. Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. J Am Coll Cardiol 52 (2008) 1391-1398
17. Kaufmann P.A., Gnecchi-Ruscone T., Schafers K.P., Luscher T.F., and Camici P.G. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol 36 (2000) 103-109
18. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S., Manes C., Fischer D., de Groot K., Fliser D., Fauler G., Marz W., and Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
19. Asselbergs F.W., van der Harst P., Jessurun G.A., Tio R.A., and van Gilst W.H. Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vasc Pharmacol 42 (2005) 125-140
20. Baller D., Notohamiprodjo G., Gleichmann U., Holzinger J., Weise R., and Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 99 (1999) 2871-2875
21. Sdringola S., Gould K.L., Zamarka L.G., McLain R., and Garner J.A. 6 Month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease. Am Heart J 155 (2008) 245-253
22. van Veldhuisen D.J., Van den Heuvel A.F., Blanksma P.K., and Crijns H.J. Ischemia and left ventricular dysfunction: a reciprocal relation?. J Cardiovasc Pharmacol 32 suppl 1 (1998) S46-S51